In vitro wound healing characteristics of amelogenins

Wound healing involves the co-ordinated actions of several cell types, soluble cell mediators and extracellular matrix (ECM). This research project intended to investigate the role of certain ECM proteins in different processes during tissue repair by studying the interaction between dermal cells and ECM. The focus has been on amelogenins, ECM proteins that under physiological conditions aggregate into spherical structures. As a resorbable biomaterial, amelogenins enhance periodontal tissue regeneration and have been introduced in the treatment of hard-to-heal ulcers. However, the mechanisms of action need to be delineated. The aim of this project was to increase the knowledge on the effects of amelogenins on cell behaviour, to further understand the role of this specific ECM protein in tissue repair and regeneration. To study the in vitro effects of amelogenins on wound healing, three human cell types; macrophages, fibroblasts, and endothelial cells, all essential for successful tissue repair, were utilised. The study designs included cell cultures, in monolayer, 3D-culture and an ex vivo model (chick aortic arch assay) for the angiogenesis studies. The evaluation methods included cell quantification, mitogenesis and apoptosis studies by BrdU incorporation and TUNEL measurements respectively, cytokine analysis by ELISA and multiplex bead array, cell surface integrin adhesion assay, gene microarray analysis, phase contrast and fluorescence microscopy for morphology and viability, and ultrastructural studies by electron microscopy. The results demonstrate that amelogenins influence the in vitro cell behaviour of all three cell types investigated. The interaction and uptake of amelogenin aggregates was demonstrated for both macrophages and fibroblasts. In addition, the possible involvement of integrin-dependent adhesion was demonstrated for fibroblasts and endothelial cells, with increased cell binding by multiple integrins subunits and αvβ3, αvβ5 and α5β1. Amelogenin treatment of cultured macrophages displayed anti-inflammatory properties, directing the release of several pro- and anti-inflammatory cytokines. In particular, induced secretion of the specific marker of alternative macrophage activation AMAC-1, along with vascular endothelial growth factor was seen, most probably resulting from a switch of macrophage phenotype to an alternatively activated cell, with tissue repair characteristics. Also, amelogenins increased cell proliferation and induced the expression of genes involved in cellular growth, migration and differentiation in normal dermal fibroblasts. Moreover, amelogenins had the capacity to restore an acute-like phenotype in senescent fibroblasts. Finally, amelogenins displayed pro-angiogenic properties in vitro and ex vivo. In conclusion, the effects of amelogenins on wound healing are plausibly, at least partly, conducted by providing macrophages, fibroblasts, and endothelial cells with tissue repair characteristics. These effects are most probably conducted through cell adhesion via integrin interaction

A Transgenic Model Reveals the Role of Klotho in Pancreatic Cancer Development and Paves the Way for New Klotho-Based Therapy

Klotho is an anti-aging transmembrane protein, which can be shed and can function as a hormone. Accumulating data indicate that klotho is a tumor suppressor in a wide array of malignancies, and designate the subdomain KL1 as the active region of the protein towards this activity. We aimed to study the role of klotho as a tumor suppressor in pancreatic ductal adenocarcinoma (PDAC). Bioinformatics analyses of The Cancer Genome Atlas (TCGA) datasets revealed a correlation between the survival of PDAC patients, levels of klotho expression, and DNA methylation, and demonstrated a unique hypermethylation pattern of klotho in pancreatic tumors. The in vivo effects of klotho and KL1 were examined using three mouse models. Employing a novel genetic model, combining pancreatic klotho knockdown with a mutation in Kras, the lack of klotho contributed to PDAC generation and decreased mousece survival. In a xenograft model, administration of viral particles carrying sKL, a spliced klotho isoform containing the KL1 domain, inhibited pancreatic tumors. Lastly, treatment with soluble sKL prolonged survival of Pdx1-Cre; KrasG12D/+;Trp53R172H/+ (KPC) mice, a model known to recapitulate human PDAC. In conclusion, this study provides evidence that klotho is a tumor suppressor in PDAC. Furthermore, these data suggest that the levels of klotho expression and DNA methylation could have prognostic value in PDAC patients, and that administration of exogenous sKL may serve as a novel therapeutic strategy to treat PDAC